<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hematopoietic stem cell transplantation is the oldest and most successful form of stem cell therapy </plain></SENT>
<SENT sid="1" pm="."><plain>High dose therapy (HDT) followed by hematopoietic stem cell transplantation allows physicians to administer increased amounts of chemotherapy and/or radiation while minimizing negative side effects such as damage to blood-producing bone marrow cells </plain></SENT>
<SENT sid="2" pm="."><plain>Although HDT is successful in treating a wide range of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, it leads to lethal therapy-related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> syndrome or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in 5--10% of patients undergoing autologous hematopoietic cell transplantation for Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we carried out metabolomic analysis of peripheral blood stem cell samples collected in a cohort of patients before hematopoietic cell transplantation to gain insights into the molecular and cellular pathogenesis of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Nonparametric tests and multivariate analyses were used to compare the metabolite concentrations in samples from patients that developed t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> within 5 years of transplantation and the patients that did not </plain></SENT>
<SENT sid="5" pm="."><plain>The results suggest that the development of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is associated with dysfunctions in cellular metabolic pathways </plain></SENT>
<SENT sid="6" pm="."><plain>The top canonical pathways suggested by the metabolomic analysis include alanine and <z:chebi fb="0" ids="29995">aspartate</z:chebi> metabolism, <z:chebi fb="1" ids="36655">glyoxylate</z:chebi> and <z:chebi fb="0" ids="28965">dicarboxylate</z:chebi> metabolism, phenylalanine metabolism, <z:chebi fb="2" ids="50744">citrate</z:chebi> acid cycle, and aminoacyl-t-<z:chebi fb="40" ids="33697">RNA</z:chebi> biosynthesis </plain></SENT>
<SENT sid="7" pm="."><plain>Dysfunctions in these pathways indicate <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> dysfunction that would result in decreased ability to detoxify reactive oxygen species generated by chemo and radiation therapy, therefore leading to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-causing mutations </plain></SENT>
<SENT sid="8" pm="."><plain>These observations suggest predisposing factors for the development of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>